Global Levetiracetam API Market Insights, Forecast to 2028

Levetiracetam is a relatively unique anticonvulsant that is typically used in combination with other antiepileptic medications for partial onset seizures. Levetiracetam has been linked to rare instances of serum aminotransferase and alkaline phosphatase elevations during treatment and to rare cases of clinically apparent drug induced liver disease.
Market Analysis and Insights: Global Levetiracetam API Market
Due to the COVID-19 pandemic, the global Levetiracetam API market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the review period. Fully considering the economic change by this health crisis, Purity≥98% accounting for % of the Levetiracetam API global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Levetiracetam Tablets segment is altered to an % CAGR throughout this forecast period.
China Levetiracetam API market size is valued at US$ million in 2021, while the US and Europe Levetiracetam API are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Levetiracetam API landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period.
The global key manufacturers of Levetiracetam API include Dr. Reddy’s Laboratories Ltd., Solara Active Pharma Sciences, Divis Laboratories Ltd., Apeloa Pharmaceutical Co., Ltd., Jiangbei Pharmaceutical, Amoli Organics, Zhejiang Huahai Pharmaceuticals Co., Ltd, Neuland Laboratories and Srini Pharmaceuticals, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
In terms of production side, this report researches the Levetiracetam API capacity, production, growth rate, market share by manufacturers and by region (region level and country level), from 2017 to 2022, and forecast to 2028.
In terms of sales side, this report focuses on the sales of Levetiracetam API by region (region level and country level), by company, by Type and by Application. from 2017 to 2022 and forecast to 2028.
Global Levetiracetam API Scope and Segment
Levetiracetam API market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Levetiracetam API market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on production capacity, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Purity≥98%
Purity<98%
Segment by Application
Levetiracetam Tablets
Levetiracetam Injections
Others
By Company
Dr. Reddy’s Laboratories Ltd.
Solara Active Pharma Sciences
Divis Laboratories Ltd.
Apeloa Pharmaceutical Co., Ltd.
Jiangbei Pharmaceutical
Amoli Organics
Zhejiang Huahai Pharmaceuticals Co., Ltd
Neuland Laboratories
Srini Pharmaceuticals
Orchid Chemicals & Pharmaceuticals
SMS Pharmaceuticals
Second Pharma Co., Ltd.
Chongqing Shenghuaxi Pharmaceutical Co., Ltd
Production by Region
India
China
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E